- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| JOYZYME GROUP Aktie jetzt für 0€ handeln | |||||
| Mo | JOYZYME GROUP (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 04.02. | HUAKANG BIOMED (08622): (1) CHANGE OF COMPANY NAME (2) CHANGE OF STOCK SHORT NAME (3) CHANGE OF COMPANY LOGO (4) CHANGE OF COMPANY WEBSITE | - | HKEx | ||
| 15.01. | HUAKANG BIOMED (08622): POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 JANUARY 2026 | - | HKEx | ||
| 23.12.25 | HUAKANG BIOMED (08622): POSTPONEMENT OF THE EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, 8 JANUARY 2026 AT 11:00 A.M. | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): PROPOSED CHANGE OF COMPANY NAME AND NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 19.12.25 | HUAKANG BIOMED (08622): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 | - | HKEx | ||
| 15.12.25 | HUAKANG BIOMED (08622): VOLUNTARY ANNOUNCEMENT EXEMPTED CONTINUING CONNECTED TRANSACTION | - | HKEx | ||
| 15.12.25 | HUAKANG BIOMED (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 15.12.25 | HUAKANG BIOMED (08622): CHANGE OF ADDRESS OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND PROPOSED CHANGE OF COMPANY NAME | - | HKEx | ||
| 12.12.25 | HUAKANG BIOMED (08622): (REVISED) COMPANY INFORMATION SHEET | 2 | HKEx | ||
| 11.12.25 | HUAKANG BIOMED (08622): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 11.12.25 | HUAKANG BIOMED (08622): JOINT ANNOUNCEMENT - CLOSE OF MANDATORY UNCONDITIONAL CASH OFFERS BY KINGSTON SECURITIES FOR AND ON BEHALF OF ANSELME LIMITED ... | - | HKEx | ||
| 09.12.25 | HUAKANG BIOMED (08622): (REVISED) NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.12.25 | HUAKANG BIOMED (08622): DISCLOSURE OF DEALINGS UNDER RULE 22 OF THE TAKEOVERS CODE | - | HKEx | ||
| 05.12.25 | HUAKANG BIOMED (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 05.12.25 | HUAKANG BIOMED (08622): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 05.12.25 | HUAKANG BIOMED (08622): ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE | 2 | HKEx | ||
| 19.11.25 | HUAKANG BIOMED (08622): COMPANY INFORMATION SHEET | 1 | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,74 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns | ||
| QIAGEN | 43,280 | +1,00 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| EVOTEC | 6,186 | +6,18 % | Bayer, Evotec oder Novo Nordisk: Dieser Biotech setzt zum Sprung an! | Seit Jahren schlagen unsere Aktien-Profis regelmäßig den Gesamtmarkt und sorgen für steile Renditen in den Anlegerdepots. So auch mit den Aktien von Bayer, Evotec oder Novo Nordisk. Doch unser Top-Favorit... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity | ||
| APOGEE THERAPEUTICS | 67,74 | -2,35 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| ZENAS BIOPHARMA | 26,520 | +1,69 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IMMUNOME | 22,160 | -1,25 % | H.C. Wainwright initiates coverage on Immunome stock with Buy rating |
Das Unternehmen JOYZYME GROUP LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOYZYME GROUP LTD finden Sie auf Wallstreet Online.